These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8491051)

  • 1. Kinetics of serum 1,84 iPTH after high dose of calcitriol in uremic patients.
    Seidel A; Herrmann P; Klaus G; Mehls O; Schmidt-Gayk H; Ritz E
    Clin Nephrol; 1993 Apr; 39(4):210-3. PubMed ID: 8491051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose oral calcitriol and changes of plasma 1,84iPTH in uremic children.
    Klaus G; Schmidt-Gayk H; Roth HJ; Ritz E; Mehls O
    Adv Perit Dial; 1994; 10():261-6. PubMed ID: 7999841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
    Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
    Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
    Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R
    Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients.
    Brossard JH; Roy L; Lepage R; Gascon-Barré M; D'Amour P
    Miner Electrolyte Metab; 1997; 23(1):25-32. PubMed ID: 9058366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulse oral calcitriol to treat hyperparathyroidism in 43 CAPD patients.
    Juergensen P; Santacroce S; Mooraki A; Cooper K; Finkelstein FO; Kliger AS
    Adv Perit Dial; 1994; 10():259-60. PubMed ID: 7999840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
    Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
    Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of oral calcitriol single weekly pulse in CAPD and in HD.
    Romanini D; Gazo A; Bellazzi R; de Vincenzi A; Nai M; Santagostino M
    Adv Perit Dial; 1994; 10():267-9. PubMed ID: 7999842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
    Grekas D; Balaskas E; Kampouris H; Benos A; Konstantinou A; Sioullis A; Tourkantonis A
    Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O
    Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
    Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
    Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,25-(OH)2-16ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect.
    Lippuner K; Perrelet R; Casez JP; Popp A; Uskokovic MR; Jaeger P
    Horm Res; 2004; 61(1):7-16. PubMed ID: 14646396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
    Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
    Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (calcitriol) therapy.
    Bellazzi R; Romanini D; Bacchella L; Nai M; Aprile C; Santagostino M; De Vincenzi A
    Nephron; 1991; 57(3):273-82. PubMed ID: 2017266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial.
    Herrmann P; Ritz E; Schmidt-Gayk H; Schäfer I; Geyer J; Nonnast-Daniel B; Koch KM; Weber U; Hörl W; Haas-Wörle A
    Nephron; 1994; 67(1):48-53. PubMed ID: 8052367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
    Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
    Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.